Tag: 100-200

In 2016,Aitha, Anjaiah; Yennam, Satyanarayana; Behera, Manoranjan; Anireddy, Jaya Shree published 《Design and synthesis of diaziridinyl quinone thiadiazole hybrids via nitrile sulfide cycloaddition reaction as a key step》.Tetrahedron Letters published the findings.Quality Control of 3-(Trifluoromethyl)-1H-pyrazole The information in the text is summarized as follows:

A series of novel diaziridinyl quinone thiadiazole hybrids (I; R = N-heterocycle) were synthesized starting from 2-hydroxy-5-methoxybenzoic acid in a 7 step synthetic sequence. The key step in the scheme involves the nitrile sulfide cycloaddition reaction of oxathiazolone II with p-tosyl cyanide to obtain 1,2,4-thiadiazole derivative III. We have demonstrated that p-tosyl group of thiadiazole 5 can be displaced with various nitrogen heterocycles to generate unknown 3,5-disubstituted thiadiazole derivatives In the experiment, the researchers used 3-(Trifluoromethyl)-1H-pyrazole(cas: 20154-03-4Quality Control of 3-(Trifluoromethyl)-1H-pyrazole)

3-(Trifluoromethyl)-1H-pyrazole(cas: 20154-03-4) belongs to pyrazoles. The application of pyrazole derivatives in the development of anticancer agents has been thoroughly investigated and verified. Moreover, the medicinal features of a number of natural products incorporating pyrazole moiety such as pyrazofurin, pyrazofurin B, pyrazole-3(5)-carboxylic acid and 4-methylpyrazole-3(5)-carboxylic acid have been reported.Quality Control of 3-(Trifluoromethyl)-1H-pyrazole

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

《Preparation of Chiral Photosensitive Organocatalysts and Their Application for the Enantioselective Synthesis of 1,2-Diamines》 was published in Journal of Organic Chemistry in 2020. These research results belong to Lyu, Jiyuan; Claraz, Aurelie; Vitale, Maxime R.; Allain, Clemence; Masson, Geraldine. Formula: C4H3F3N2 The article mentions the following:

Chiral phosphoric acid based organocatalysis and visible-light photocatalysis have both emerged as promising technologies for the sustainable production of fine chems. In this context, we have envisioned the design and the synthesis of a new class of chimeric catalytic entities that would feature both catalytic capabilities. Given their multitask nature, such catalysts would be particularly attractive for the development of new catalytic transformations, tandem processes in particular. Toward this goal, several BINOL-based chiral phosphoric acid backbones presenting one or two visible-light-sensitive thioxanthone moieties have been prepared and studied. The utility of these new photoactive chiral organocatalysts is then demonstrated in the enantioselective tandem three-component electrophilic amination of enecarbamates. Of note, the C1-sym. organo/photocatalyst has shown a better catalytic activity than those presenting a C2 symmetry. After reading the article, we found that the author used 3-(Trifluoromethyl)-1H-pyrazole(cas: 20154-03-4Formula: C4H3F3N2)

3-(Trifluoromethyl)-1H-pyrazole(cas: 20154-03-4) belongs to pyrazoles. The application of pyrazole derivatives in the development of anticancer agents has been thoroughly investigated and verified. Moreover, the medicinal features of a number of natural products incorporating pyrazole moiety such as pyrazofurin, pyrazofurin B, pyrazole-3(5)-carboxylic acid and 4-methylpyrazole-3(5)-carboxylic acid have been reported.Formula: C4H3F3N2

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

In 2012,Sandoval, Angel; Chokshi, Aalap; Jesch, Elliot D.; Black, Paul N.; DiRusso, Concetta C. published 《Identification and characterization of small compound inhibitors of human FATP2 [Erratum to document cited in CA152:421565]》.Biochemical Pharmacology published the findings.Reference of 3-(Trifluoromethyl)-1H-pyrazole The information in the text is summarized as follows:

On page 997, Compound CB-5 in Table 3B contained a structure error; the corrected structure is given. In the experimental materials used by the author, we found 3-(Trifluoromethyl)-1H-pyrazole(cas: 20154-03-4Reference of 3-(Trifluoromethyl)-1H-pyrazole)

3-(Trifluoromethyl)-1H-pyrazole(cas: 20154-03-4) belongs to pyrazoles. The application of pyrazole derivatives in the development of anticancer agents has been thoroughly investigated and verified. Moreover, the medicinal features of a number of natural products incorporating pyrazole moiety such as pyrazofurin, pyrazofurin B, pyrazole-3(5)-carboxylic acid and 4-methylpyrazole-3(5)-carboxylic acid have been reported.Reference of 3-(Trifluoromethyl)-1H-pyrazole

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

In 2010,Sandoval, Angel; Chokshi, Aalap; Jesch, Elliot D.; Black, Paul N.; Di Russo, Concetta C. published 《Identification and characterization of small compound inhibitors of human FATP2》.Biochemical Pharmacology published the findings.Application In Synthesis of 3-(Trifluoromethyl)-1H-pyrazole The information in the text is summarized as follows:

Fatty acid transport proteins (FATPs) are bifunctional proteins, which transport long chain fatty acids into cells and activate very long chain fatty acids by esterification with CoA. In an effort to understand the linkage between cellular fatty acid transport and the pathol. associated with excessive accumulation of exogenous fatty acids, we targeted FATP-mediated fatty acid transport in a high throughput screen of more than 100,000 small diverse chem. compounds in yeast expressing human FATP2 (hsFATP2). Compounds were selected for their ability to depress the transport of the fluorescent long chain fatty acid analog, C1-BODIPY-C12. Among 234 hits identified in the primary screen, 5 compounds, each representative of a structural class, were further characterized in the human Caco-2 and HepG2 cell lines, each of which normally expresses FATP2, and in 3T3-L1 adipocytes, which do not. These compounds were effective in inhibiting uptake with IC50s in the low micromolar range in both Caco-2 and HepG2 cells. Inhibition of transport was highly specific for fatty acids and there were no effects of these compounds on cell viability, trans-epithelial elec. resistance, glucose transport, or long chain acyl-CoA synthetase activity. The compounds were less effective when tested in 3T3-L1 adipocytes suggesting selectivity of inhibition. These results suggest fatty acid transport can be inhibited in a FATP-specific manner without causing cellular toxicity. In addition to this study using 3-(Trifluoromethyl)-1H-pyrazole, there are many other studies that have used 3-(Trifluoromethyl)-1H-pyrazole(cas: 20154-03-4Application In Synthesis of 3-(Trifluoromethyl)-1H-pyrazole) was used in this study.

3-(Trifluoromethyl)-1H-pyrazole(cas: 20154-03-4) belongs to pyrazoles. The application of pyrazole derivatives in the development of anticancer agents has been thoroughly investigated and verified. Moreover, the medicinal features of a number of natural products incorporating pyrazole moiety such as pyrazofurin, pyrazofurin B, pyrazole-3(5)-carboxylic acid and 4-methylpyrazole-3(5)-carboxylic acid have been reported.Application In Synthesis of 3-(Trifluoromethyl)-1H-pyrazole

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

In 1956,Monte, Dea Dal; Mangini, Angelo; Passerini, Riccardo published 《Heterocyclics-ultraviolet absorption spectra and chromophoric properties. III. Pyrazoles and phenylpyrazoles》.Gazzetta Chimica Italiana published the findings.Quality Control of Methyl 1H-pyrazole-3-carboxylate The information in the text is summarized as follows:

Fifty known substituted pyrazoles and phenylpyrazoles were prepared and their near ultraviolet absorption spectra were recorded in alc., alc.-water, cyclohexane, HCl, and alkali. Spectra were plotted, and absorption maximum and mol. extinction coefficients were tabulated. Substituents were Me, CO2R, Et, NH2, and NO2. Changes in spectra, mol. refraction, and basicities for pyrazole and Me derivatives confirmed a hyperconjugation effect for Me in 5- and 3-positions. Pyrazolecarboxylic acids and esters showed conjugation of CO with ring. The 208 mμ band was associated with the chromophore C:CCO2H. The 200-210 mμ band in pyrazole was assigned to the first excited level, antisymmetric combination, type B1. N-Phenylpyrazole showed conjugation between rings or between ring and imine, depending on substitution position, while 5-Me and 2-Me compounds were sterically hindered. Nitration in position 4 or 4′ caused conjugation of NO2 with imine.Methyl 1H-pyrazole-3-carboxylate(cas: 15366-34-4Quality Control of Methyl 1H-pyrazole-3-carboxylate) was used in this study.

Methyl 1H-pyrazole-3-carboxylate(cas: 15366-34-4) belongs to pyrazoles. The application of pyrazole derivatives in the development of anticancer agents has been thoroughly investigated and verified. Moreover, the medicinal features of a number of natural products incorporating pyrazole moiety such as pyrazofurin, pyrazofurin B, pyrazole-3(5)-carboxylic acid and 4-methylpyrazole-3(5)-carboxylic acid have been reported.Quality Control of Methyl 1H-pyrazole-3-carboxylate

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

Safety of 1-Butyl-1H-pyrazoleOn September 30, 1990 ,《Synthesis of N-alkylpyrazoles by phase transfer catalysis without solvent》 was published in Synthetic Communications. The article was written by Diez-Barra, E.; De la Hoz, A.; Sanchez-Migallon, A.; Tejeda, J.. The article contains the following contents:

The reaction of alkyl halides with pyrazoles in the presence of Bu4N+ Br- without solvent gave 36-98% N-alkylpyrazoles I [R = Me(CH2)n, PhCH2, CH2:CHCH2, CH2:C:CH; n = 0, 1, 3, 7, 15].1-Butyl-1H-pyrazole(cas: 52096-24-9Safety of 1-Butyl-1H-pyrazole) was used in this study.

1-Butyl-1H-pyrazole(cas: 52096-24-9) belongs to pyrazoles. Pyrazoles and their related multiring analogs are common elements of a wide variety of bioactive compounds. These ring structures are rare in nature. A consequence of this is that they have previously been thought to be poor moieties to include in potential new drugs. Safety of 1-Butyl-1H-pyrazole

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

Reference of 3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazoleIn 2009 ,《A convenient and rapid approach for the synthesis of 1-benzyl-3-heterocyclic pyrazoles》 appeared in Tetrahedron Letters. The author of the article were Curtis, Michael P.; Sammons, Matthew F.; Piotrowski, David W.. The article conveys some information:

A variety of 1-benzyl-3-hetarylpyrazoles were rapidly assembled by a 2-step N-benzylation/Suzuki coupling sequence using a 3-pyrazolylboronate and benzyl bromides as starting compounds A 1-pot variation of this sequence is demonstrated. The results came from multiple reactions, including the reaction of 3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(cas: 844501-71-9Reference of 3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole)

3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(cas: 844501-71-9) belongs to pyrazoles. Pyrazoles are commonly used scaffold molecules in drug discovery projects. The use of pyrazole derivatives is based on their analgesic, antipyretic, neuroleptic, anticonvulsant, antiarrhythmic, sedative, muscle relaxant, monoamine oxidase inhibitory, anti-inflammatory, antidiabetic and antibacterial activities. Reference of 3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

HPLC of Formula: 20154-03-4In 2020 ,《Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer》 appeared in Journal of Medicinal Chemistry. The author of the article were He, Yali; Hwang, Dong-Jin; Ponnusamy, Suriyan; Thiyagarajan, Thirumagal; Mohler, Michael L.; Narayanan, Ramesh; Miller, Duane D.. The article conveys some information:

We report herein the design, synthesis, and pharmacol. characterization of a library of novel aryl pyrazol-1-yl-propanamides as selective androgen receptor degraders (SARDs) and pan-antagonists that exert broad-scope AR antagonism. Pharmacol. evaluation demonstrated that introducing a pyrazole moiety as the B-ring structural element in the common A-ring-linkage-B-ring nonsteroidal antiandrogens’ general pharmacophore allowed the development of a new scaffold of small mols. with unique SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-155 and UT-34. Novel B-ring pyrazoles exhibited potent AR antagonist activities, including promising distribution, metabolism, and pharmacokinetic properties, and broad-spectrum AR antagonist properties, including potent in vivo antitumor activity. I was able to induce an 80% tumor growth inhibition of xenografts derived from the enzalutamide-resistant (Enz-R) VCaP cell line. These results represent an advancement toward the development of novel AR antagonists for the treatment of Enz-R prostate cancer. After reading the article, we found that the author used 3-(Trifluoromethyl)-1H-pyrazole(cas: 20154-03-4HPLC of Formula: 20154-03-4)

3-(Trifluoromethyl)-1H-pyrazole(cas: 20154-03-4) belongs to pyrazoles. Pyrazole derivatives have been reported to exhibit a wide range of applications in medicinal chemistry and pharmacology. A large number of drugs incorporating pyrazole structure have been utilized as partial agonists for nicotinic acid receptors, antidepressants, antimicrobial agents, antiviral agents, and antifungal agents solely or along with the combination of other structural motifs.HPLC of Formula: 20154-03-4

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

Sun, Mingli; Zhou, Yuhui; Li, Laiqiang; Wang, Lei; Ma, Yongmin; Li, Pinhua published an article in 2021. The article was titled 《Electrochemically promoted C-3 amination of 2H-indazoles》, and you may find the article in Organic Chemistry Frontiers.Computed Properties of C5H6N2O2 The information in the text is summarized as follows:

A metal-free and external oxidant-free electrochem. method for the C-3 amination of 2H-indazoles was reported for the synthesis of indazolyl-amines I [R = n-Bu, 1-pyrazolyl, morpholino, etc.; R1 = H, 5-F, 6-Br, etc.; R2 = Ph, 1-naphthyl, 2-pyridyl, etc.]. The protocol employed com. available azoles and aliphatic amines as amination reagents and had a broad substrate scope, providing the corresponding C3-amination products in high yields at room temperature Mechanistic studies indicated that an oxidative addition/elimination sequence was involved under electrochem. conditions. In the part of experimental materials, we found many familiar compounds, such as Methyl 1H-pyrazole-3-carboxylate(cas: 15366-34-4Computed Properties of C5H6N2O2)

Methyl 1H-pyrazole-3-carboxylate(cas: 15366-34-4) belongs to pyrazoles. The application of pyrazole derivatives in the development of anticancer agents has been thoroughly investigated and verified. Moreover, the medicinal features of a number of natural products incorporating pyrazole moiety such as pyrazofurin, pyrazofurin B, pyrazole-3(5)-carboxylic acid and 4-methylpyrazole-3(5)-carboxylic acid have been reported.Computed Properties of C5H6N2O2

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

In 2019,Frontiers in Pharmacology included an article by Shim, Heesung; Brown, Brandon M.; Singh, Latika; Singh, Vikrant; Fettinger, James C.; Yarov-Yarovoy, Vladimir; Wulff, Heike. Name: 3-(Trifluoromethyl)-1H-pyrazole. The article was titled 《The trials and tribulations of structure assisted design of KCa channel activators》. The information in the text is summarized as follows:

Calcium-activated K+ channels constitute attractive targets for the treatment of neurol. and cardiovascular diseases. To explain why certain 2-aminobenzothiazole/oxazole-type KCa activators (SKAs) are KCa3.1 selective we previously generated homol. models of the C-terminal calmodulin-binding domain (CaM-BD) of KCa3.1 and KCa2.3 in complex with CaM using Rosetta modeling software. We here attempted to employ this atomistic level understanding of KCa activator binding to switch selectivity around and design KCa2.2 selective activators as potential anticonvulsants. In this structure-based drug design approach we used RosettaLigand docking and carefully compared the binding poses of various SKA compounds in the KCa2.2 and KCa3.1 CaM-BD/CaM interface pocket. Based on differences between residues in the KCa2.2 and KCa.3.1 models we virtually designed 168 new SKA compounds The compounds that were predicted to be both potent and KCa2.2 selective were synthesized, and their activity and selectivity tested by manual or automated electrophysiol. However, we failed to identify any KCa2.2 selective compounds Based on the full-length KCa3.1 structure it was recently demonstrated that the C-terminal crystal dimer was an artifact and suggested that the “”real”” binding pocket for the KCa activators is located at the S4-S5 linker. We here confirmed this structural hypothesis through mutagenesis and now offer a new, corrected binding site model for the SKA-type KCa channel activators. SKA-111 (5-methylnaphtho[1,2-d]thiazol-2-amine) is binding in the interface between the CaM N-lobe and the S4-S5 linker where it makes van der Waals contacts with S181 and L185 in the S45A helix of KCa3.1. The experimental part of the paper was very detailed, including the reaction process of 3-(Trifluoromethyl)-1H-pyrazole(cas: 20154-03-4Name: 3-(Trifluoromethyl)-1H-pyrazole)

3-(Trifluoromethyl)-1H-pyrazole(cas: 20154-03-4) belongs to pyrazoles. The application of pyrazole derivatives in the development of anticancer agents has been thoroughly investigated and verified. Moreover, the medicinal features of a number of natural products incorporating pyrazole moiety such as pyrazofurin, pyrazofurin B, pyrazole-3(5)-carboxylic acid and 4-methylpyrazole-3(5)-carboxylic acid have been reported.Name: 3-(Trifluoromethyl)-1H-pyrazole

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics